Coppola G, Pascotto A
Child Neuropsychiatry Clinic, Department of Pediatrics, Second University of Naples, Italy.
Brain Dev. 1996 Jan-Feb;18(1):50-2. doi: 10.1016/0387-7604(95)00110-7.
We report the results of a double-blind, placebo-controlled cross-over trial with allopurinol as add-on therapy in childhood refractory epilepsy. Seventeen patients received allopurinol and matched placebo for 12 weeks in 2 doses (10 mg/kg/day during the first week and 15 mg/kg/day thereafter with a washout period of 2 weeks between treatment phases. The total number of seizures was reduced by 50-98% in 4 patients (23.5%) and by 25-49% in another 4 (23.5%). However, the number of seizures remained unchanged in 5 patients (29.4%) and worsened in 4 (23.5%). Adverse side effects (17.6%) were generally mild and transient, suggesting that allopurinol is well-tolerated. A mean follow-up of 10 months of the responders did not show any relevant efficacy of allopurinol as an adjuvant therapy for refractory epilepsy, even at high doses.
我们报告了一项双盲、安慰剂对照的交叉试验结果，该试验使用别嘌醇作为儿童难治性癫痫的附加疗法。17名患者接受了别嘌醇和匹配的安慰剂治疗，为期12周，分两个剂量阶段（第一周10毫克/千克/天，此后15毫克/千克/天，治疗阶段之间有2周的洗脱期）。4名患者（23.5%）的癫痫发作总数减少了50 - 98%，另外4名患者（23.5%）减少了25 - 49%。然而，5名患者（29.4%）的癫痫发作次数保持不变，4名患者（23.5%）的发作情况恶化。不良副作用发生率为17.6%，一般较轻且为短暂性，这表明别嘌醇耐受性良好。对有反应者平均随访10个月发现，即使是高剂量的别嘌醇作为难治性癫痫的辅助治疗也未显示出任何相关疗效。
